Raymond James Financial Inc. Buys Shares of 1,765,593 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Raymond James Financial Inc. purchased a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 1,765,593 shares of the company’s stock, valued at approximately $38,914,000. Raymond James Financial Inc. owned 0.16% of Teva Pharmaceutical Industries at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. FMR LLC lifted its position in Teva Pharmaceutical Industries by 30.7% in the fourth quarter. FMR LLC now owns 81,983,231 shares of the company’s stock worth $1,806,910,000 after purchasing an additional 19,242,468 shares during the period. Clal Insurance Enterprises Holdings Ltd raised its stake in shares of Teva Pharmaceutical Industries by 12.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock worth $859,935,000 after buying an additional 4,418,961 shares in the last quarter. Lingotto Investment Management LLP lifted its holdings in shares of Teva Pharmaceutical Industries by 2.6% in the fourth quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company’s stock valued at $599,320,000 after buying an additional 688,862 shares during the period. Migdal Insurance & Financial Holdings Ltd. boosted its stake in Teva Pharmaceutical Industries by 2.2% during the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company’s stock valued at $573,822,000 after buying an additional 569,412 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Teva Pharmaceutical Industries by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 9,281,052 shares of the company’s stock worth $203,642,000 after acquiring an additional 489,041 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Trading Down 0.1 %

Shares of NYSE TEVA opened at $13.59 on Wednesday. The firm has a market capitalization of $15.40 billion, a PE ratio of -9.37, a PEG ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The business has a 50-day moving average price of $15.64 and a two-hundred day moving average price of $17.76.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on TEVA shares. Bank of America reduced their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Piper Sandler raised their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. UBS Group cut their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Barclays reduced their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. Finally, StockNews.com lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Monday. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.